89614-56-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-Nuciferine is used as a weight-loss supplement for its potential to modulate glucose and lipid metabolism, thereby aiding in the management of obesity and related metabolic disorders.
Used in Anti-diabetic Applications:
In the pharmaceutical industry, (R)-Nuciferine is utilized as an anti-diabetic agent, targeting the regulation of glucose and lipid metabolism to improve insulin sensitivity and reduce blood sugar levels in diabetic patients.
Used in Psychiatric Treatments:
(R)-Nuciferine is employed as a novel treatment for schizophrenia and other psychiatric disorders, leveraging its anti-psychotic properties to modulate neurotransmitter levels and alleviate symptoms associated with these conditions.
Overall, (R)-1-(4-METHOXY-BENZYL)-2-METHYL-1,2,3,4,5,6,7,8-OCTAHYDRO-ISOQUINOLINE, or (R)-Nuciferine, demonstrates its potential as a multi-faceted therapeutic agent with applications in weight management, diabetes treatment, and psychiatric care, offering promising benefits in the field of medicine and healthcare.

Upstream product

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 119-65-3 isoquinoline 
• 100466-47-5 N-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 100466-46-4 N-benzyl-5,6,7,8-tetrahydroisoquinolinium bromide 
• 100466-49-7 ((S)-1-tert-Butoxymethyl-2-methyl-propyl)-[1-[(S)-1-(4-methoxy-benzyl)-3,4,5,6,7,8-hexahydro-1H-isoquinolin-2-yl]-meth-(E)-ylidene]-amine 
• 100466-48-6 ((S)-1-tert-Butoxymethyl-2-methyl-propyl)-[1-(3,4,5,6,7,8-hexahydro-1H-isoquinolin-2-yl)-meth-(E)-ylidene]-amine 
• 2721-62-2 1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 29144-31-8 (S)-2-Formyl-1-<(4-methoxyphenyl)methyl>-1,2,3,4,5,6,7,8-octahydroispquinoline 
• 38969-65-2 1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline 
• 30356-07-1 (1S)-1-[(4-methoxyphenyl)methyl]-1,2,3,4,5,6,7,8-octahydroisoquinoline 

Downstream Products

• 125-73-5 (+)-dextrorphan 
• 852334-50-0 {2-[2-(4-methoxy-phenethyl)-cyclohexyl]-ethyl}-methyl-amine 
• 95367-72-9 {2-[2-(4-methoxy-phenethyl)-cyclohexyl]-ethyl}-dimethyl-amine 
• 102021-29-4 {2-[2-(4-methoxy-styryl)-cyclohex-1-enyl]-ethyl}-dimethyl-amine 

Relevant academic research and scientific papers

On the formation of a side product with hexahydroaporphine-like structure in the Grewe cyclization of dextromethorphan

Factors leading to the formation of a hexahydroaporphine-like cyclizing side product were studied systematically for the first time and the ratio of this side product was controlled effectively. To understand better the electronic effect of substrates on the formation of side products, different 1-benzyloctahydroisoquinolines with substituted groups on nitrogen or benzene ring were compared. A plausible mechanism of cyclizing reaction was proposed, and key intermediates as well as transition states were analyzed using DFT calculations.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia.